Cardiol Therapeutics (CRDL) Competitors $1.21 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CRDL vs. ALLO, TERN, AKBA, ABVX, CDXC, KOD, NMRA, ORGO, KALV, and AURAShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Allogene Therapeutics (ALLO), Terns Pharmaceuticals (TERN), Akebia Therapeutics (AKBA), ABIVAX Société Anonyme (ABVX), ChromaDex (CDXC), Kodiak Sciences (KOD), Neumora Therapeutics (NMRA), Organogenesis (ORGO), KalVista Pharmaceuticals (KALV), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Allogene Therapeutics Terns Pharmaceuticals Akebia Therapeutics ABIVAX Société Anonyme ChromaDex Kodiak Sciences Neumora Therapeutics Organogenesis KalVista Pharmaceuticals Aura Biosciences Cardiol Therapeutics (NASDAQ:CRDL) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends. Does the media prefer CRDL or ALLO? In the previous week, Allogene Therapeutics had 7 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 7 mentions for Allogene Therapeutics and 0 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.87 beat Allogene Therapeutics' score of -0.06 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cardiol Therapeutics Very Positive Allogene Therapeutics Neutral Does the MarketBeat Community prefer CRDL or ALLO? Allogene Therapeutics received 256 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 65.57% of users gave Allogene Therapeutics an outperform vote while only 63.16% of users gave Cardiol Therapeutics an outperform vote. CompanyUnderperformOutperformCardiol TherapeuticsOutperform Votes2463.16% Underperform Votes1436.84% Allogene TherapeuticsOutperform Votes28065.57% Underperform Votes14734.43% Do analysts prefer CRDL or ALLO? Cardiol Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 623.14%. Allogene Therapeutics has a consensus target price of $9.73, indicating a potential upside of 434.80%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Allogene Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Is CRDL or ALLO more profitable? Allogene Therapeutics' return on equity of -52.13% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -194.40% -129.07% Allogene Therapeutics N/A -52.13%-41.29% Which has more volatility & risk, CRDL or ALLO? Cardiol Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Which has better earnings and valuation, CRDL or ALLO? Cardiol Therapeutics has higher earnings, but lower revenue than Allogene Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol TherapeuticsN/AN/A-$20.84M-$0.39-3.10Allogene Therapeutics$43K8,874.49-$327.27M-$1.56-1.17 Do institutionals & insiders have more ownership in CRDL or ALLO? 12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 24.3% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAllogene Therapeutics beats Cardiol Therapeutics on 10 of the 17 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.86M$2.96B$5.36B$9.09BDividend YieldN/A1.94%5.13%4.03%P/E Ratio-3.1045.5689.4717.33Price / SalesN/A358.911,253.32134.80Price / CashN/A192.9043.7535.97Price / Book3.783.975.324.80Net Income-$20.84M-$41.02M$122.60M$224.91M7 Day Performance-5.47%8.62%0.87%1.90%1 Month Performance-9.70%10.70%4.80%5.08%1 Year Performance14.15%5.54%27.90%21.15% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics2.4573 of 5 stars$1.21flat$8.75+623.1%+18.6%$98.86MN/A-3.1020Positive NewsALLOAllogene Therapeutics2.652 of 5 stars$1.94-5.8%$9.73+401.7%-42.2%$406.76M$43,000.00-1.24310TERNTerns Pharmaceuticals4.2296 of 5 stars$4.74-5.4%$18.30+286.1%-20.8%$402.61M$1M-4.0240AKBAAkebia Therapeutics3.8789 of 5 stars$1.84+5.1%$7.50+307.6%+45.8%$401.45M$169.88M-8.00430Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageABVXABIVAX Société Anonyme2.285 of 5 stars$6.31-1.1%$38.67+512.8%-46.5%$399.73MN/A0.0061Short Interest ↑Positive NewsCDXCChromaDex4.6424 of 5 stars$5.22-0.9%$8.00+53.3%+315.4%$398.72M$91.67M522.52120Analyst DowngradeShort Interest ↑KODKodiak Sciences3.608 of 5 stars$7.49-10.0%$8.00+6.8%+120.6%$394.15MN/A-2.0590Short Interest ↑Positive NewsGap DownNMRANeumora Therapeutics3.6818 of 5 stars$2.39+8.1%$16.50+590.4%-85.5%$386.13MN/A-1.28108Analyst ForecastORGOOrganogenesis4.4577 of 5 stars$2.96-1.7%$5.00+68.9%-13.7%$372.15M$455.04M-49.33950News CoveragePositive NewsKALVKalVista Pharmaceuticals4.3228 of 5 stars$7.51-4.3%$25.00+232.9%-36.2%$371.13MN/A-2.06150AURAAura Biosciences2.2151 of 5 stars$7.42-2.4%$23.00+210.0%-1.0%$370.64MN/A-4.2950Short Interest ↑News CoveragePositive News Related Companies and Tools Related Companies ALLO Alternatives TERN Alternatives AKBA Alternatives ABVX Alternatives CDXC Alternatives KOD Alternatives NMRA Alternatives ORGO Alternatives KALV Alternatives AURA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRDL) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
